Medicare expands cancer prevention: genetic testing and preventive surgery now covered
H.R. 4752 — Reducing Hereditary Cancer Act · Filed by Debbie Wasserman Schultz (D-FL) · 32 cosponsors · Introduced Jul 23, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands Medicare coverage for genetic testing to identify hereditary cancer risk, preventive surgeries for people at high genetic risk, and more frequent cancer screenings for those with hereditary cancer mutations. It allows Medicare to pay for germline mutation testing, risk-reducing surgeries (like preventive mastectomies), and annual or more frequent screenings based on clinical guidelines—benefiting Medicare beneficiaries at genetic risk of cancers like breast, ovarian, and colon cancer.
Why we flagged it
The bill's core function is to amend Medicare law (Social Security Act) to add coverage for hereditary cancer genetic testing, risk-reducing surgeries, and enhanced screening protocols. It is a straightforward public-health and insurance-coverage measure.
What the text implies
- The bill delegates coverage-determination authority to Medicare Administrative Contractors (MACs), which may create regional variation in what tests and surgeries are covered, potentially leading to inconsistent access across the country.
- The phrase 'least restrictive' guidelines may incentivize broader testing and surgery recommendations, increasing Medicare spending and potentially driving unnecessary procedures in borderline cases.
The full analysis lists 4 implications of this text.
Who stands to gain
genetic testing companies; cancer screening providers (imaging centers, endoscopy centers); surgical oncology practices